Short-term Revision of USP Chapter on Dissolution Testing

Recommendation
10/11 September 2025
On 29 December 2011, the USP announced that the appropriate experts group of the USP had revised General Chapter <711> - Dissolution Testing. This revision will enter into force on 1st February 2012.
The background for the revision is the removal of Chlorpheniramine Maleate Extended-Release Tablets RS from the list of reference standards and from the Apparatus Suitability section.
The standard used until now had turned out and couldn't be replaced.
The USP is currently in the process of identifying replacement materials to be used in the Performance Verification Test for Apparatus 3.
The revised Chapter will be integrated in the second supplement of USP 35 - NF 30.
Further information is available in the Revision Bulletin - General Chapter <711> Dissolution as well as in the revised chapter.
Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls
25.06.2025FDA Warning Letter: "Memory-Based Manufacturing" and Lack of Analytical Testing
11.06.2025USP informs about Monographs affected by the Revision of NMR Chapters <761> and <1761>
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies